Učitavanje...
Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data
Canagliflozin (CFZ) is a member of new class of glucose lowering agents, sodium-glucose co-transporter (SGLT) inhibitors, which got approval by food and drug administration. It has insulin independent action by blocking the transporter protein SGLT2 in the kidneys, resulting in urinary glucose excre...
Spremljeno u:
| Glavni autori: | , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Baishideng Publishing Group Inc
2014
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4058745/ https://ncbi.nlm.nih.gov/pubmed/24936262 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4239/wjd.v5.i3.399 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|